CA Patent

CA3094693A1 — Rimegepant for cgrp related disorders

Assigned to Pfizer Ireland Pharmaceuticals · Expires 2019-10-03 · 7y expired

What this patent protects

Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions a…

USPTO Abstract

Disclosed are methods of treating CGRP related disorders, e.g., migraine, by administering to a patient in need thereof rimegepant or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising rimegepant and kits including the pharmaceutical compositions and instructions are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
CA3094693A1
Jurisdiction
CA
Classification
—
Expires
2019-10-03
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Ireland Pharmaceuticals
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.